Raja Mutharasan, MD
Cardiovascular Disease · Chicago, ILNPI 1780704791
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $123,931 of the $145,785 with a category attached, or 85.0%. 17 manufacturers reported payments, led by AstraZeneca at 43.3% of the total. 2025 is the largest year on record at $53,367, more than ten times the $33 reported in 2019. Among cardiovascular disease clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $899.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$63K
- Novo Nordisk$60K
- Abbott$9K
- Amgen$7K
- GE HealthCare$5K
- Heartflow, Inc.$580
- plus $923 from 11 others
Across 2 payments — averaging $3600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Caption Health, Inc.$7K
What the payments were for
- Consulting fees$9,6707%
- Speaking & faculty fees$123,93185%
- Travel & lodging$5,2664%
- Food & beverage$6,9045%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $63,187 |
| Novo Nordisk | 49 | $60,393 |
| Abbott | 20 | $9,259 |
| Amgen | 8 | $6,631 |
| GE HealthCare | 3 | $4,813 |
| Heartflow, Inc. | 1 | $580 |
| Boehringer Ingelheim | 4 | $264 |
| Edwards Lifesciences | 3 | $257 |
| Cardiovascular Systems Inc. | 2 | $144 |
| Medtronic | 1 | $103 |
| Sensible Medical Innovations Inc | 1 | $40 |
| Novartis | 1 | $29 |
| Boston Scientific | 1 | $23 |
| Merck | 1 | $17 |
| Cvrx, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Pfizer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$62,519
- Wegovy$49,587
- MitraClip System$8,446
- FFRct$580
- Repatha$480
- JARDIANCE$214
- CARDIOMEMS$167
- MitraClip$155
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$141
- SAPIEN 3 Ultra RESILIA$126
- Ozempic$121
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$114
- Diamondback Coronary$107
- COREVALVE EVOLUT R$103
How this compares
$145,785 in reported general payments places this provider in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 201 | $255,794 |
| EntrestoSacubitril/Valsartan | 82 | $114,355 |
| JardianceEmpagliflozin | 52 | $81,588 |
| XareltoRivaroxaban | 54 | $63,139 |
| Repatha SureclickEvolocumab | 45 | $47,501 |
| FarxigaDapagliflozin Propanediol | 36 | $43,929 |
| Metoprolol Succinate | 334 | $5,293 |
| Atorvastatin Calcium | 352 | $4,546 |
| Ezetimibe | 116 | $2,353 |
| Spironolactone | 255 | $2,251 |
| Rosuvastatin Calcium | 130 | $2,178 |
| Bumetanide | 92 | $2,100 |
| Carvedilol | 103 | $1,295 |
| Colchicine | 22 | $1,238 |
| Potassium Chloride | 26 | $1,165 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $13 | $255,794201 claims |
| NovartisEntresto | $29 | $114,35582 claims |
| Boehringer IngelheimJardiance | $264 | $81,58852 claims |
| AstraZenecaFarxiga | $63,187 | $43,92936 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 932 cardiovascular disease providers in Illinois.
Other cardiovascular disease in Chicago
- Sandeep NathanChicago$892K
- Boaz AvitallChicago$366K
- Akhil NarangChicago$363K
- Michael DavidsonChicago$317K
- Jyothy PuthumanaChicago$269K
- Sanjiv ShahChicago$246K
- Nitasha SarswatChicago$140K
- Evan SteinChicago$121K
- Dan FintelChicago$119K
- Elizabeth McNallyChicago$119K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.